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http://www.biomedcentral.com/1741-7015/11/180RESEARCH ARTICLE Open AccessPlasma procalcitonin is associated with all-cause
and cancer mortality in apparently healthy men: a
prospective population-based study
Ovidiu S Cotoi1, Jonas Manjer2, Bo Hedblad2, Gunnar Engström2, Olle Melander2 and Alexandru Schiopu2,3*Abstract
Background: The inflammatory mediator procalcitonin (PCT) has previously been associated with prognosis in
myocardial infarction, cancer and sepsis patients. The importance of PCT in the general population is currently
unknown. Our aim was to assess the relationship between plasma PCT and the risk of all-cause and cause-specific
mortality in apparently healthy individuals with no previous history of cardiovascular disease or cancer.
Methods: We performed a prospective, population-based study on 3,322 individuals recruited from the Malmö Diet
and Cancer cohort, with a median follow-up time of 16.2 years. Plasma PCT, high-sensitivity C-reactive protein
(hsCRP), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and cystatin C were measured at
baseline and a thorough risk factor assessment was performed for all subjects. The primary end-points of the study
were all-cause mortality, cancer mortality and cardiovascular mortality.
Results: Men had higher PCT levels compared to women. In Cox proportional hazard models adjusted for age, sex,
hypertension, diabetes, plasma lipids, renal function, body mass index and smoking, baseline PCT was associated
with all-cause mortality and cancer mortality in men. The hazard ratio (HR) for men with PCT levels within the
highest compared with the lowest quartile was 1.52 (95% confidence interval (CI) 1.07 to 2.16; P = 0.024) for
all-cause mortality and 2.37 (95% CI 1.36 to 4.14; P = 0.006) for cancer mortality. Additionally, men with increased
plasma PCT were found to be at a higher risk to develop colon cancer (HR per 1 SD increase = 1.49 (95% CI 1.13 to
1.95); P = 0.005). In multivariate Cox regression analyses with mutual adjustments for PCT and hsCRP, PCT was
independently associated with cancer death (HR per 1 SD increase = 1.28 (95% CI 1.10 to 1.49); P = 0.001) and
hsCRP with cardiovascular death (HR per 1 SD increase = 1.42 (95% CI 1.11 to 1.83); P = 0.006) in men. We found no
significant correlations between baseline PCT or hsCRP and incident cancer or cardiovascular death in women.
Conclusions: We disclose for the first time important independent associations between PCT and the risk for
all-cause and cancer mortality in apparently healthy men. Our findings warrant further investigation into the
mechanisms underlying the relationship between PCT and cancer.
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Inflammation plays a central role in the pathogenesis of
cardiovascular (CV) disease [1] and cancer [2], the two
most common causes of death worldwide among non-
communicable diseases [3]. The inflammatory biomarker
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reproduction in any medium, provided the orwith CV morbidity and mortality in the general popula-
tion and has been shown to mildly improve CV risk pre-
diction on top of the Framingham Risk Score [4].
Numerous immune and inflammatory conditions have
been linked to increased risk of cancer development [5].
Plasma hsCRP has been shown to predict the incidence
of certain types of cancer [6] and has been linked to the
risk of all-cause and cancer death [7,8].
Procalcitonin (PCT) is the precursor of the hormone
calcitonin which functions as a regulator of calciumtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is secreted under homeostatic conditions by the neuro-
endocrine cells of the thyroid gland and lungs [9]. PCT
concentrations are low in healthy individuals but increase
dramatically in the systemic inflammatory response syn-
drome (SIRS) associated with severe infections and sepsis
[10] as well as with trauma, surgery, burns and pancrea-
titis [11]. The levels of PCT reflect disease severity and
predict resolution and prognosis [10,12,13]. Under these
conditions it has been suggested that the entire body may
become a source of PCT, as Calc1 mRNA was found to be
expressed in almost all tissues examined in animal models
of sepsis [14,15]. PCT was shown to have pro-inflammatory
and immunosuppressive properties and to be actively
involved as a mediator of disease progression and se-
verity in sepsis [15-17].
The importance of PCT under homeostatic conditions
in the general population has been studied to a much
lesser extent. Due to the importance of PCT as an im-
mune and inflammatory mediator we hypothesized that
PCT might be involved in pathologic conditions other
than SIRS and sepsis. We have recently demonstrated a
positive association between the levels of plasma PCT in
an unselected population of apparently healthy individ-
uals and the incidence of coronary events and CV death
[18]. However, PCT did not provide supplementary
information for CV risk prediction due to a high degree of
co-variation with hsCRP and traditional CV risk factors,
such as diabetes and blood pressure [18].
Here we investigate whether plasma PCT in apparently
healthy individuals with no previous history of cancer or
CV disease is associated with total and cause-specific
mortality. Additionally, we assessed whether there are
gender-specific differences with regard to the value of
PCT as a mortality predictor, as men have generally
higher baseline PCT levels than women [18]. PCT was
analyzed alone and in comparison with hsCRP. We
demonstrate that PCT is strongly associated with the
risk of all-cause and cancer mortality and with the inci-
dence of colon cancer in men, independently of smoking,
diabetes, hypertension, body mass index (BMI), plasma
lipids, renal function and hsCRP. In contrast, hsCRP was
independently associated with CV mortality but not with
cancer mortality in men. Neither biomarker was corre-
lated with incident mortality in women, after adjustment
for potential confounding risk factors.
Methods
Study design and population
The study population was part of the CV arm of the
Malmö Diet and Cancer (MDC) cohort [19]. The MDC
is a population-based prospective cohort of 28,449 indi-
viduals enrolled between 1991 and 1996. The CV arm of
the MDC includes 6,094 subjects selected for the studyof CV disease [20]. Out of this cohort we excluded 89
individuals who had previously been diagnosed with cor-
onary disease or stroke and an additional 619 subjects
who had a previous cancer diagnosis. Of the remaining
individuals, overnight fasting plasma samples for PCT
measurement were available for 3,322 subjects. The
characteristics of the included and excluded subjects are
presented in Table 1 and Additional file 1: Table S1. None
of the participants had clinical signs of infection upon en-
rollment and hsCRP values were within the normal range
(Table 1). All participants provided written informed con-
sent and the study was approved by the ethical committee
at Lund University, Sweden and conducted in accordance
with the Helsinki declaration.
Data collection
All participants provided a medical history and underwent
a physical examination. Cigarette smoking was assessed by
a self-administered questionnaire and was defined as any
smoking within the past year. Blood pressure was measured
after resting for 10 minutes in the supine position. Hyper-
tension was defined as systolic blood pressure (SBP) ≥140
mmHg, diastolic blood pressure (DBP) ≥90 mmHg or use
of antihypertensive medication. Diabetes mellitus was de-
fined as a fasting whole-blood glucose level >6.0 mmmol/L,
a self-reported physician diagnosis of diabetes or use of
antidiabetic medication. Plasma lipids were measured at
the Department of Clinical Chemistry, Skane University
Hospital. CRP concentration was determined using a
high-sensitivity assay (Tina-Quant CRP, Roche Diagnostics,
Basel, Switzerland). Cystatin C was measured using a
particle-enhanced immunonephelometric assay (N Latex
Cystatin C, Dade Behring, Deerfield, IL, USA). Serum PCT
concentration was determined by an ultrasensitive assay
(ProCa-S; BRAHMS GmbH, Hennigsdorf, Germany). The
lower detection limit of the assay was 10 pg/mL and
the functional assay sensitivity (the lowest value with
an inter-assay coefficient of variation below 20%) was
17 pg/mL, as reported by the assay manufacturer.
Study endpoints
We studied total mortality and mortality due to CV, ma-
lignant, infectious, endocrine, neurological, psychiatric,
respiratory, digestive, urogenital, musculoskeletal and
dermatological diseases. Secondary endpoints were total
cancer incidence, as well as the incidence of colon, rec-
tum, lung and bronchi, breast, prostate, urinary tract
and skin cancers. In order to ensure adequate power,
only cancer diagnoses with more than 20 incident events
during follow-up were included in the analysis. Events
were identified through linkage of the 10-digit personal
identification number of each Swedish citizen with three
registries: the Swedish Hospital Discharge Register, the
Swedish Cause of Death Register and the Swedish Cancer
Table 1 Characteristics of the study population at baseline
Characteristic Population Men Women PCT quartiles
Q1 Q2 Q3 Q4
Number of participants (%) 3,322 1,467 (44) 1,855 (56) 935 820 760 807
Age, mean (SD), years 58 (6) 58 (6) 58 (6) 56 (6) 57 (6) 58 (6) 59 (6)
Blood pressure, mean (SD), mm Hg
Systolic 142 (19) 143 (18) 140 (19) 137 (18) 140 (18) 145 (19) 146 (19)
Diastolic 87 (9) 89 (9) 86 (9) 85 (9) 86 (9) 88 (9) 89 (9)
Hypertension, Number (%) 2,118 (63.8) 991 (67.6) 1,127 (60.8) 508 (54.3) 506 (61.7) 510 (67.1) 594 (73.6)
Lipids, mean (SD), mmol/L
LDL-C 4.17 (0.98) 4.12 (0.90) 4.20 (1.04) 4.05 (1.00) 4.11 (0.94) 4.30 (0.99) 4.22 (0.97)
HDL-C 1.38 (0.37) 1.22 (0.29) 1.52 (0.37) 1.52 (0.38) 1.41 (0.36) 1.32 (0.35) 1.26 (0.33)
TG 1.31 (0.63) 1.43 (0.68) 1.21 (0.57) 1.11 (1.00) 1.22 (0.55) 1.40 (0.66) 1.53 (0.73)
Body mass index, mean (SD), kg/m2 25.7 (3.9) 26.0 (3.4) 25.5 (4.2) 24.9 (3.7) 25.3 (3.7) 26.1 (3.7) 26.8 (4.0)
Diabetes mellitus, Number (%) 272 (8.2) 158 (10.8) 114 (6.1) 42 (4.5) 41 (5.0) 71 (9.3) 118 (14.6)
Current smoking, Number (%) 861 (25.9) 412 (28.1) 449 (24.2) 251 (26.8) 221 (27.0) 205 (27.0) 184 (22.8)
Cystatin C, mean (SD), mg/L 0.77 (0.14) 0.79 (0.15) 0.75 (0.13) 0.72 (0.12) 0.76 (0.12) 0.79 (0.13) 0.83 (0.17)
hsCRP, median (IQR), mg/L 0.13 0.12 0.13 0.10 0.11 0.13 0.20
(0.06 to 0.28) (0.06 to 0.27) (0.06 to 0.28) (0.05 to 0.20) (0.06 to 0.24) (0.07 to 0.27) (0.09 to 0.41)
PCT, median (IQR), pg/mL 16 (13 to 20) 18 (15 to 23) 14 (12 to 18) 12 (10 to 13) 15 (14 to 16) 18 (17 to 19) 25 (22 to 30)
Men 14 (12 to 15) 17 (16 to 18) 20 (19 to 21) 28 (25 to 34)
Women 10 (9 to 11) 13 (12 to 14) 16 (15 to 17) 21 (19 to 25)
hsCRP, high sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; PCT,
procalcitonin; TG, triglycerides.
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registries has previously been validated [21], and the
sensitivity of the registry for detecting events such as
myocardial infarction has been shown to exceed 90%
[22]. Approximately 99% of all tumors diagnosed at
Swedish Hospitals are registered in the SCR and 98%
are morphologically verified [23]. Tumor site was reg-
istered according to the International Classification of
Diseases, revision 7 (ICD-7) and the ICD version used
at diagnosis. Pathological type was coded according to
the C24 classification [23]. CV death was defined using
codes 390 to 459 (IDC9) and I codes (ICD10) as the
main cause of death in the cause of death registry.
Statistical analysis
SPSS software (version 19, SPSS Inc, Chicago, IL, USA)
was used for all statistical calculations. The values for
PCT and hsCRP were logarithmically transformed before
being included in the analysis. We performed multivariate
Cox proportional hazards analyses to assess the associations
between baseline PCT and the risk of all-cause mortality,
cancer mortality, CV mortality and combined mortality
by other causes. We used two different models adjusted
for: (1) age and sex and (2) age, sex, and other risk factors
previously associated with morbidity and mortality in the
general population (hypertension, BMI, HDL, LDL, TG,
diabetes mellitus and smoking) as well as cystatin C as asurrogate marker of renal function, with and without fur-
ther adjustment for hsCRP. Data were expressed as hazard
ratios (HR) and 95% confidence intervals (CI). Further,
we tested whether PCT is related to the incidence of
different types of cancer using a Cox proportional haz-
ards model adjusted for age and sex. A two-sided value
of P < 0.05 was considered statistically significant. Receiver
operating characteristic (ROC) analyses were used to




We investigated whether increased plasma PCT levels in
apparently healthy individuals with no previous history
of CV disease or cancer are associated with higher
mortality risk. During a median follow-up period of 16.2
years (IQR 15.6 to 16.8), 434 (13%) of the study subjects
died. Cancer was the most common single cause of
death in the study population (201 cases), followed by CV
disease (121 cases) (Table 2). Injuries and poison (21), re-
spiratory (20), neurological (20), digestive (12), psychiatric
(9), endocrine, metabolic and immune (6), infectious (4),
urogenital (2), dermatological (2) and musculoskeletal (1)
diseases accounted for 97 deaths. The cause of death was
unknown for 14 individuals. Due to the low number of
deaths of each separate cause, deaths due to causes other
Table 2 Correlation between PCT quartiles and mortality adjusted for age and sex
Subjects Outcome Number
of eventsa
Q2 versus Q1 Q3 versus Q1 Q4 versus Q1 P for linear
trendHR (95% CI) HR (95% CI) HR (95% CI)
All subjects All-cause mortality 8.39 1.05 (0.77 to 1.43) 1.29 (0.96 to 1.73) 1.63 (1.22 –to 2.17) <0.001***
Cancer mortality 3.88 1.07 (0.69 to 1.68) 1.47 (0.96 to 1.25) 1.60 (1.04 to 2.43) 0.014*
CVD mortality 2.34 1.24 (0.67 to 2.29) 1.30 (0.71 to 2.36) 1.94 (1.09 to 3.42) 0.016*
Mortality from causes other
than cancer and CVD
2.16 0.92 (0.50 to 1.68) 1.08 (0.60 to 1.93) 1.49 (0.86 to 2.60) 0.096
Men All-cause mortality 11.14 0.98 (0.67 to 1.45) 0.98 (0.68 to 1.42) 1.50 (1.08 to 2.09) 0.020*
Cancer mortality 4.92 1.54 (0.86 to 2.75) 1.23 (0.68 to 2.21) 1.96 (1.15 to 3.35) 0.027*
CVD mortality 3.13 0.74 (0.34 to 1.61) 0.86 (0.43 to 1.72) 1.41 (0.76 to 2.60) 0.208
Mortality from causes other
than cancer and CVD
3.09 0.65 (0.03 to 1.40) 0.86 (0.44 to 1.67) 1.15 (0.62 to 2.12) 0.557
Women All-cause mortality 6.30 1.45 (0.86 to 2.46) 1.57 (0.91 to 2.71) 2.04 (1.22 to 2.34) 0.004*
Cancer mortality 3.13 1.51 (0.77 to 2.99) 1.25 (0.59 to 2.62) 1.62 (0.81 to 3.23) 0.295
CVD mortality 1.74 1.18 (0.36 to 3.86) 1.91 (0.61 to 6.00) 2.73 (0.93 to 8.06) 0.012*
Mortality from causes other
than cancer and CVD
1.46 1.66 (0.52 to 5.25) 2.17 (0.68 to 6.96) 2.40 (0.78 to 7.38) 0.106
Cox regression analysis adjusted for age and sex. aExpressed per 1,000 person years. CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; PCT,
procalcitonin; Q, quartile. *P <0.05, ***P <0.001.
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had higher mortality compared to women (Table 2). Risk
factor prevalence in the population by PCT quartile is
presented in Table 1 and by cause of death in Additional
file 1: Table S2.
In a crude Kaplan-Meyer analysis we found that the
cumulative incidence of all-cause mortality in the study
population increased by quartile of baseline plasma PCT
concentration (Figure 1). Further, we examined the associ-
ation between PCT quartiles, total mortality, cancer mor-
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Figure 1 Total mortality in the study population during follow-up
by baseline PCT quartile. Kaplan – Meier plot showing 1 minus total
survival by PCT quartiles: first (lowest values) to fourth quartile of the
baseline plasma PCT concentration. PCT, procalcitonin.Cox proportional hazards model corrected for age and sex
(Table 2). We analyzed the entire cohort as a whole, and
men and women separately. We found significant positive
relationships between PCT and the risk of total mortality,
cancer and CV mortality in the entire study population.
The association between PCT and total mortality remained
valid when men and women were analyzed separately.
However, PCT predicted cancer mortality only in men and
CV mortality only in women. PCT did not predict death
by causes other than CV disease and cancer in any of the
considered groups.
In order to assess whether PCT is independently related
to mortality risk we conducted a Cox regression analysis
further adjusted for BMI, smoking, hypertension, LDL,
HDL, TG, diabetes mellitus and cystatin C (Table 3).
Cystatin C was included in the adjusted model, as we have
found a significant correlation between PCT quartiles and
cystatin C in our cohort (Table 1; Spearman correlation
coefficient 0.304, P <0.001). These results are in accordance
with previous data showing that renal function influences
plasma PCT concentrations [24]. The correlations between
PCT, total mortality and cancer mortality in the entire
cohort remained significant after adjustment. However,
these relationships seem to be supported by a strong
correlation between PCT and cancer mortality in men.
Men having baseline PCT concentrations within the
fourth quartile had a 2.37 (95% CI (1.36 to 4.14)) times
higher risk of dying from cancer compared to men within
the first quartile. The correlations between PCT, total mor-
tality and CV mortality in women completely lost statistical
significance after risk factor adjustment.
We have previously described a high degree of co-
variation between PCT and hsCRP in healthy individuals,
Table 3 Correlation between PCT quartiles and mortality adjusted for age, sex, hypertension, diabetes, plasma lipids,
renal function, BMI and smoking
Subjects Outcome Number
of eventsa
Q2 versus Q1 Q3 versus Q1 Q4 versus Q1 P for linear
trendHR (95% CI) HR (95% CI) HR (95% CI)
All subjects All-cause mortality 8.39 1.04 (0.76 to 1.42) 1.22 (0.90 to 1.65) 1.52 (1.13 to 2.06) 0.002**
Cancer mortality 3.88 1.11 (0.70 to 1.74) 1.56 (1.01 to 2.41) 1.78 (1.13 to 2.77) 0.004**
CVD mortality 2.34 1.18 (0.64 to 2.19) 1.01 (0.55 to 1.85) 1.42 (0.79 to 2.57) 0.266
Mortality from causes other
than cancer and CVD
2.16 0.90 (0.49 to 1.66) 1.07 (0.59 to1.93) 1.47 (0.82 to 2.63) 0.126
Men All-cause mortality 11.14 0.99 (0.67 to 1.47) 0.96 (0.66 to 1.40) 1.52 (1.07 to 2.16) 0.024*
Cancer mortality 4.92 1.71 (0.95 to 3.07) 1.38 (0.76 to 2.50) 2.37 (1.36 to 4.14) 0.006**
CVD mortality 3.13 0.66 (0.30 to 1.45) 0.69 (0.34 to 1.39) 1.18 (0.62 to 2.25) 0.539
Mortality from causes other
than cancer and CVD
3.09 0.71 (0.33 to 1.53) 0.91 (0.46 to 1.78) 1.28 (0.67 to 2.45) 0.428
Women All-cause mortality 6.30 1.29 (0.76 to 2.20) 1.37 (0.79 to 2.38) 1.61 (0.94 to 2.75) 0.081
Cancer mortality 3.13 1.43 (0.72 to 2.83) 1.17 (0.55 to 2.48) 1.57 (0.76 to 3.23) 0.352
CVD mortality 1.74 0.86 (0.27 to 2.97) 1.38 (0.43 to 4.44) 1.47 (0.47 to 4.62) 0.245
Mortality from causes other
than cancer and CVD
1.46 1.50 (0.47 to 4.77) 1.93 (0.59 to 6.28) 1.90 (0.58 to 6.16) 0.281
Cox regression analysis adjusted for age, sex, hypertension, diabetes, LDL, HDL, TG, renal function, BMI and smoking. aExpressed per 1,000 person years. BMI, body
mass index; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; PCT, procalcitonin; Q,
quartile; TG, triglycerides. *P <0.05, **P <0.01.
Cotoi et al. BMC Medicine 2013, 11:180 Page 5 of 9
http://www.biomedcentral.com/1741-7015/11/180which restricts the value of PCT as an independent pre-
dictor of CVD [18]. Here, we explored the value of PCT
and hsCRP as independent mortality predictors in Cox re-
gression analyses adjusted for traditional risk factors and
mutually adjusted for each other (Table 4). PCT maintained
significant associations with total mortality and cancer mor-
tality in the whole population and in men, independently of
hsCRP. In turn, hsCRP was independently associated with
CV mortality, which is in line with our previous resultsTable 4 Comparative analysis of the associations between PC
Subjects Outcome
All subjects All-cause mortality
Cancer mortality
CVD mortality








Mortality from causes other than cancer and CVD
Cox regression analysis adjusted for age, sex, hypertension, diabetes, LDL, HDL, TG,
per quartile of the respective biomarker. BMI, body mass index; CI, confidence inter
hsCRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; PCT, procalc[18]. We found no relationship between hsCRP, all-cause
and cancer death in this model. Neither biomarker was
associated with mortality in women.
PCT and the incidence of cancer
We further explored whether PCT is associated with the
incidence of a particular type of cancer. There were 601
cases of incident cancer during follow-up, with an equal
total distribution between men and women (Table 5).T, hsCRP and incident mortality
PCT hsCRP
HR (95% CI)a P HR (95% CI)a P
1.15 (1.04 to 1.26) 0.006** 1.08 (0.98 to 1.19) 0.100
1.23 (1.06 to 1.41) 0.005** 1.02 (0.89 to 1.16) 0.788
1.08 (0.89 to 1.30) 0.425 1.24 (1.03 to 1.49) 0.025*
1.15 (0.95 to 1.39) 0.161 1.07 (0.89 to 1.28) 0.483
1.13 (1.00 to 1.27) 0.047* 1.09 (0.97 to 1.23) 0.156
1.29 (1.08 to 1.54) 0.006** 0.96 (0.80 to 1.14) 0.632
1.04 (0.83 to 1.30) 0.741 1.30 (1.01 to 1.66) 0.037*
1.07 (0.86 to 1.34) 0.556 1.16 (0.92 to 1.47) 0.220
1.13 (0.97 to 1.32) 0.106 1.07 (0.92 to 1.24) 0.362
1.09 (0.88 to 1.35) 0.430 1.13 (0.92 to 1.38) 0.261
1.19 (0.87 to 1.62) 0.286 1.13 (0.84 to 1.51) 0.433
1.21 (0.87 to 1.67) 0.251 0.92 (0.68 to 1.23) 0.568
renal function, BMI and smoking. aThe HR values are expressed as mean HR
val; CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio;
itonin; TG, triglycerides. *P <0.05, **P <0.01.
Table 5 PCT and the incidence of cancer
Cancer subtype All subjects Men Women
N HRa Pb N HRa Pc N HRa Pc
(95% CI) (95% CI) (95% CI)
Total cancer incidence 520 1.02 (0.93 to 1.12) 0.611 257 1.08 (0.96 to 1.21) 0.184 263 0.97 (0.86 to 1.11) 0.705
Colon 36 1.18 (0.90 to 1.55) 0.238 19 1.49 (1.13 to 1.95) 0.005** 17 0.59 (0.31 to 1.13) 0.108
Rectum 34 1.16 (0.86 to 1.57) 0.343 15 1.14 (0.71 to 1.83) 0.583 19 1.15 (0.79 to 1.67) 0.469
Lung and bronchi 43 0.95 (0.68 to 1.33) 0.764 23 0.95 (0.62 to 1.46) 0.819 20 0.96 (0.59 to 1.54) 0.864
Urinary tract 36 0.87 (0.59 to 1.27) 0.467 22 0.86 (0.55 to 1.35) 0.515 14 0.93 (0.52 to1.68) 0.815
Malignant melanoma 22 1.00 (0.64 to 1.57) 0.999 14 1.17 (0.74 to 1.87) 0.499 8 0.64 (0.26 to 1.62) 0.348
Skin (excluding melanoma) 29 0.88 (0.65 to 1.45) 0.879 19 1.12 (0.74 to 1.70) 0.600 10 0.59 (0.25 to 1.38) 0.225
Prostate 130 1.02 (0.86 to 1.21) 0.841
Breast 122 1.00 (0.83 to 1.20) 0.998
aExpressed per 1 SD increment. Cox regression analysis adjusted for age and sexb or agec. CI, confidence interval; HR, hazard ratio; PCT, procalcitonin. **P <0.01.
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cer in men and breast cancer in women. Only cancer
subtypes with more than 20 incident events in the entire
population were considered for the statistical analysis. In
a Cox proportional hazards model corrected for age and
sex, PCT was significantly associated with the incidence of
colon cancer in men (Table 5). We found no relationship
between PCT and cancer incidence in women. BMI,
smoking and hsCRP were previously shown to be asso-
ciated with the incidence of cancer [6,25,26] and renal
function influences the concentration of plasma PCT
[24]. After additional adjustment for BMI, smoking,
hsCRP and cystatin C the association between PCT and
colon cancer incidence in men remained statistically
significant (HR per 1 SD PCT increment (95% CI) = 1.45
(1.03 to 2.04); P = 0.034).
PCT as clinical predictor of morbidity and mortality in men
As PCT is independently correlated with morbidity and
mortality in men, we further investigated whether PCT
may represent a robust clinical predictor of total mortality,
cancer mortality and colon cancer incidence in men. The
areas under the ROC curve (AUC) were 0.573 (95% CI
(0.532 to 0.614)) for total mortality, 0.586 (95% CI (0.531
to 0.642)) for cancer mortality and 0.705 (95% CI (0.619
to 0.791)) for the incidence of colon cancer. Due to
the modest AUC values and the low incidence of colon
cancer in the male population in our study, we were
not able to establish clear cut-off values with good
sensitivity and specificity for PCT as a morbidity and
mortality predictor in men.
Discussion
Our data reveal a previously undisclosed relationship
between plasma PCT levels in apparently healthy indi-
viduals and the risk of future mortality. PCT presented
gender-specific association patterns. In men, PCT was
correlated with the incidence of total mortality andcancer mortality, independently of previously disclosed
risk factors for cancer and CVD. Additionally, we
found that higher PCT levels were related to increased
incidence of colon cancer. However, the subsequent
ROC analyses suggested that PCT probably has limited
value as a clinical predictor of cancer morbidity and
mortality in apparently healthy men. In women, PCT
was associated with the risk of total mortality and CV
mortality, but the associations lost statistical significance
after taking possible confounders into account. In a com-
parative analysis adjusted for possible confounders and
each other, PCT was associated with all-cause and cancer
mortality and hsCRP with CV mortality in the entire study
population and in men analyzed separately. Neither bio-
marker predicted mortality in women.
The value of PCT as a biomarker in certain types of
cancer has previously been investigated. PCT has been
shown to have both a diagnostic and a prognostic value in
thyroid cancer, as it is mainly produced in the neuroendo-
crine C cells of the thyroid gland [27]. In patients with
solid tumors who developed febrile neutropenia during
chemotherapy, elevated PCT was associated with treat-
ment failure, death and sepsis [28]. A recently published
study demonstrated similar results in non-neutropenic
cancer patients [29].
All the studies performed so far on PCT and cancer
included patients with already diagnosed disease. We are
the first to report a link between higher plasma PCT
levels in individuals with no previous history of cancer
and increased risk of cancer mortality. The biological
importance of PCT in vivo at low concentrations in healthy
individuals has so far been unexplored. Chronic inflam-
mation plays a pathogenic role in tumor initiation and
progression [2] and hsCRP has previously been shown
to predict total cancer incidence and the incidence of
certain types of cancer in healthy individuals [6]. It has
been shown that all tissues, including the ubiquitously
present adipose tissue, are able to produce PCT under
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products [15]. However, the specific stimuli of PCT secre-
tion in healthy individuals other than bacterial endotoxin
are currently unknown. PCT presented distinct association
patterns with cancer and CV disease compared to hsCRP,
suggesting that plasma PCT might reflect specific ongoing
subclinical inflammatory processes rather than being a
global marker of systemic inflammation, such as hsCRP.
Approximately 15% of malignancies worldwide are
believed to be related to chronic infections [30] through
mechanisms involving chronic local inflammation leading
to DNA damage and mutagenesis [31]. In sepsis PCT plays
a dual role as a diagnostic and prognostic biomarker
and as a disease mediator, due to its pro-inflammatory
and immunosuppressive properties [15]. In experimental
models of sepsis, administration of antibodies against PCT
markedly increased survival of hamsters and pigs [32] and
PCT has been proposed as a therapeutic target in sepsis
patients [15]. Clinically relevant doses of PCT, similar to
those achieved in sepsis, induced the secretion of the
pro-inflammatory cytokines TNFα, IL-1β and IL-6 in
whole human blood cells in vitro [16]. In turn, TNFα is
a strong stimulator of PCT production and IL-1β and
IL-6 have been linked with elevated PCT levels, thus
creating potential pro-inflammatory positive feedback loops
[15,33,34]. TNFα, IL-6 and IL-17 are important links be-
tween chronic inflammation and tumor development [35].
Of note, although a monocyte chemoattractant in itself,
PCT suppresses chemokine-induced human monocyte
migration [17] and inhibits human neutrophil mobility
in vitro [16]. Hypothetically, the high-responders, who have
increased PCT levels under homeostatic conditions, may
produce higher and more sustained amounts of PCT under
bacterial and inflammatory stimulation. Subsequently, PCT
may amplify the pro-carcinogenic inflammatory response
and impair the anti-tumor immune mechanisms, thus
acting as a disease mediator in cancer.
Although inflammation is thought to play an import-
ant role in the pathogenesis of cancer, not all types of
cancer manifest the same pattern of association with in-
flammatory markers and mediators. CRP was previously
shown to predict the incidence of cancer of any type,
lung and colorectal cancer, but not breast or prostate
cancer [6]. Here, we demonstrate a significant independent
association between PCT levels in healthy individuals and
the incidence of colon cancer. This relationship was only
valid in men, who generally have higher plasma PCT
concentrations than women [18]. Among the different
types of cancer, colorectal cancer has one of the strongest
documented associations with inflammation [36]. Patients
suffering from local chronic inflammatory conditions such
as Crohn’s disease and ulcerative colitis run a markedly in-
creased risk of developing colorectal cancer, depending on
the duration and the extent of the disease [36]. The PCTstimulators TNFα and IL-1β are actively involved in the
pathogenesis of colon cancer and have been proposed as
therapeutic targets for anti-cancer therapy [37].
The main limitations of our study are related to the
relatively low numbers of subjects within each individual
cancer subtype group, except for prostate and breast
cancer. Based on a population of 3,322 individuals from
the general population, our study was underpowered for
detecting relationships between PCT and individual cancer
subtypes. The lack of association between PCT and the
other considered tumor subtypes does not rule out with
certainty the hypothesis that such relationships might exist.
Larger and more specifically powered studies are needed in
order to detect whether particular cancer subtypes, poten-
tially those related to infectious and inflammatory condi-
tions, drive the demonstrated association between PCT and
cancer mortality. PCT measurements in healthy men using
the ProCa-S assay are robust, as most PCT values in this
population lie above the reported functional sensitivity of
the assay of 17 pg/mL. However, exact determinations of
plasma PCT concentrations in healthy women are less
reliable due to the generally lower PCT levels in this
group. Subsequently, we cannot exclude with certainty
that this limitation of the assay might have contributed
to the observed lack of correlation between plasma PCT
and mortality in women.
Conclusions
In conclusion, we demonstrate for the first time in a large
prospective study that baseline PCT levels are independently
associated with all-cause and cancer mortality in apparently
healthy men with no previous history of cancer or CV dis-
ease. Additionally, we found a significant relationship be-
tween PCT and the incidence of colon cancer in men. PCT
and hsCRP seem to have complementary value as mortality
risk predictors. In comparative analyses mutually adjusted
for each other, PCT was independently associated with all-
cause and cancer death and hsCRP was correlated with CV
death in men, but not in women. The lack of independent
association between these biomarkers of systemic inflamma-
tion and mortality in women after accounting for traditional
risk factors may have important implications for the design
and interpretation of future biomarker studies on cardiovas-
cular disease and cancer. PCT levels have previously been
shown to be associated with prognosis in sepsis, cancer and
CV disease patients. Our study extends these findings in
healthy individuals and warrants further investigation into
the mechanisms linking PCT with the risk of cancer.
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